Health ❯Healthcare ❯Pharmaceuticals

Drug Approval

Alzheimer's Disease FDA Approval FDA Regulatory Agencies Lecanemab Alzheimer's Treatment Weight Loss Drugs Ozempic Wegovy Attruby Eli Lilly Alzheimer's Disease Treatment FDA Actions Anaphylaxis Treatment Nemluvio Psychedelic Drugs Chronic Graft-versus-Host Disease Regulatory Affairs Cancer Treatment Alzheimer's Treatments Novo Nordisk Kisqali Dupixent Niemann-Pick Disease Niemann-Pick Disease Type C Schizophrenia Antibody Therapy Parkinson's Disease Bimekizumab Zanidatamab-hrii Mounjaro and Wegovy Tirzepatide Obesity Treatments Weight-loss Drugs Weight Loss Medications Eli Lilly Zepbound GLP-1 Receptor Agonists Esketamine AZT and AIDS Pain Management Non-Opioid Painkillers Non-opioid Analgesics Nonopioid Analgesics Neurofibromatosis Nemolizumab FDA Regulations Fenfluramine Clinical Trials Breast Cancer Treatment FDA Approval Process Epinephrine Nasal Spray Abaloparatide NHS Treatments NHS Emergency Treatments Nasal Spray Epinephrine Delivery MDMA

EU Drug Agency Recommends Approval of First Alzheimer’s Treatment Targeting Disease Progression

FDA Approves Journavx, First Non-Opioid Painkiller in Over 20 Years

FDA Approves Ozempic to Reduce Kidney Disease Risks in Type 2 Diabetes Patients

FDA Approves Ozempic for Chronic Kidney Disease in Type 2 Diabetes Patients

FDA Approves First Nasal Spray for Treatment-Resistant Depression

Johnson & Johnson to Acquire Intra-Cellular Therapies in $14.6 Billion Deal

Medicare to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment

Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial

FDA Approves Zepbound as First Drug Treatment for Sleep Apnea

Growing Demand for Weight-Loss Drugs in the UK Raises Safety and Accessibility Concerns

FDA Approves Zanidatamab for Advanced HER2-Positive Biliary Tract Cancer

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

Scotland Faces Health Crisis Linked to Weight-Loss Injections

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

FDA Approves Vyalev for Advanced Parkinson's Disease Treatment

FDA Declares End to Tirzepatide Shortage, Impacting Compounded Drug Market

Ontario, Quebec, Nunavut to Offer Universal RSV Protection for Infants

FDA Approves Regeneron-Sanofi's Dupixent for COPD Treatment

FDA Approves First Treatment for Niemann-Pick Disease Type C

FDA Expands Approval of Kisqali for Early-Stage Breast Cancer

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs

FDA Declines MDMA for PTSD Treatment, Requests Further Trials

FDA Approves Neffy, the First Needle-Free Epinephrine Nasal Spray for Anaphylaxis

FDA Approves Neffy: First Needle-Free Epinephrine Nasal Spray for Allergic Reactions

New Osteoporosis Drug Approved for Postmenopausal Women in England

New Alzheimer's Drugs Face Scrutiny Over Efficacy and Safety

Eli Lilly's Zepbound Shows Promise in Reducing Heart Failure Risks

EU Regulator Denies Approval for Alzheimer's Drug Lecanemab